论文部分内容阅读
共征集374例早孕妇女于负压吸宫术前随机口服米非司酮25mg q12h×4(组Ⅰ,n=124)、米索前列醇800μm(组Ⅱ,n=126)或不用任何药物(组Ⅲ,n=124)。结果显示组Ⅰ～Ⅲ Hegar氏扩张器无阻力通过宫颈内口的最大直径分别为6.6±0.8,7.0±00.9和4.1±1.4mm((?)±S,下同);术中出血量分别为15.4±12.0,11.4±9.6和23.1±18.5ml;术中副反应发生率分别为32.26,27.78％和54.03％。三组间均有极显著差异(P<0.0001),且米索扩张宫颈和减少术中出血的临床效果比米非司酮更明显。
A total of 374 pregnant women with early pregnancy were enrolled in this study. Mifepristone 25 mg q12h × 4 (group Ⅰ, n = 124), misoprostol 800 μm (group Ⅱ, n = 126) or no medication Group III, n = 124). The results showed that the maximum diameters of non-resistance Heijiang dilators through the cervix were 6.6 ± 0.8,7.0 ± 00.9 and 4.1 ± 1.4mm (± s ± s, respectively), the blood loss were 15.4 ± 12.0, 11.4 ± 9.6 and 23.1 ± 18.5ml respectively. The incidences of intraoperative side effects were 32.26, 27.78% and 54.03% respectively. The three groups were significantly different (P <0.0001), and the clinical efficacy of misoprostol and reduce intraoperative bleeding more obvious than mifepristone.